Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) insider Douglas Kerr sold 1,564 shares of the stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $28,715.04. Following the sale, the insider owned 170,042 shares of the company’s stock, valued at approximately $3,121,971.12. This represents a 0.91% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dyne Therapeutics Price Performance
Shares of NASDAQ:DYN opened at $17.29 on Friday. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 1 year low of $8.06 and a 1 year high of $25.00. The business has a fifty day simple moving average of $18.34 and a 200 day simple moving average of $18.63. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -5.37 and a beta of 1.08.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the business earned ($1.05) EPS. As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.
Dyne Therapeutics News Roundup
- Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
- Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
- Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
- Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
- Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.
Analyst Ratings Changes
Several equities analysts have weighed in on DYN shares. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. JPMorgan Chase & Co. cut their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a report on Tuesday, January 20th. Chardan Capital restated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a report on Monday, March 9th. Morgan Stanley cut their target price on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Finally, Sanford C. Bernstein raised their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $35.00.
Check Out Our Latest Stock Report on DYN
Hedge Funds Weigh In On Dyne Therapeutics
Institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC bought a new position in shares of Dyne Therapeutics in the first quarter worth about $26,000. Chung Wu Investment Group LLC bought a new position in shares of Dyne Therapeutics in the third quarter worth about $30,000. Strs Ohio bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Dyne Therapeutics in the fourth quarter worth about $84,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the period. 96.68% of the stock is currently owned by institutional investors.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Stories
- Five stocks we like better than Dyne Therapeutics
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
